Company Overview and News
The Federal Reserve meeting today will be watched closely to see what the central bank does now and what it says about the future path of rates. The Federal Open Market Committee members are presently sounding hawkish, with policy makers being widely expected to hike rates by 25 basis points at the meeting and signal at a more aggressive path of increases.
BAC BRK.A BAC AMNB BHBK FNFV LAZ FNF
How strong is the economy? The weekly jobless claims chimed in at 201,000, the lowest level in 49 years. Yet Wells Fargo (NYSE:WFC) is laying off as many as 26,500 employees, not a great a piece of news if you own Wells Fargo stock.
WFCNP SIVB BAC USB AAPL ORCL WFC IBM BRK.A JPM BK OCLCF
October 2018 Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-224523 Preliminary Pricing Supplement
This pricing supplement, which is not complete and may be changed, relates to an effective Registration Statement under the Securities Act of 1933. This pricing supplement and the accompanying prospectus supplement and prospectus are not an offer to sell these notes in any country or jurisdiction where such an offer would not be permitted. Filed Pursuant to Rule 424(b)(2) Registration Statement No.
It’s always fun to dig through a major hedge fund and institutional investors 13-F reports to see what the “gurus” find interesting in the market. Naturally, Warren Buffett’s and his lieutenant stock picks are often at the top of most investors must see list. And in this quarters 13-F, Buffett made a big-time purchase of the Vampire Squid itself- Goldman Sachs (NYSE:GS).
BAC USB GS BRK.A JPM
2018-09-22 seekingalpha - 1
Together with its Canadian peers, it is a core holding in my dividend growth portfolio and one I will substantially increase over the years.
BAC C RY TNTTF BMO TD BNS BAC BMO RY BNS JPM TD
Over the last five trading days, major banks’ rally continued on expectation of interest rate hike this month. The rate hike will translate into top-line expansion for banks, leading to improved results in the quarters ahead. Further, given the growth in economy, low unemployment rate and healthy consumer sentiment, the demand for loans and other related products of banks are expected to rise. However, imposition of tariffs on $200 billion worth of Chinese goods next week could escalate trade war tensions, impacting consumers and increasing inflation.
WFCNP FITBI BAC USB WFC BAC C MBFI UTX MBFIP EOG FITB
The index made strong gains this week as investors shrugged off trade tensions. Trump’s decision to impose fresh tariffs on $200 billion of Chinese imports did weigh on investors. But the recent raft of positive economic data helped investors focus on broader fundamentals. Financials gained after yields on U.S. government bonds surged substantially. Tech majors also defied tariff worries to post strong gains.
BAC GS GLSSP DIS JBK BAC PFZ C GSC TFG MA PFIZER GSJ V MSFT GJS 500680 PFE
In the latest trading session, Bank of America (BAC - Free Report) closed at $31.19, marking a +0.61% move from the previous day. This move lagged the S&P 500's daily gain of 0.78%. At the same time, the Dow added 0.95%, and the tech-heavy Nasdaq gained 0.98%.
BAC BAC UNFI
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to BAC / Bank of America Corp. on message board site Silicon Investor.
as of ET